|Bid||107.35 x 900|
|Ask||107.44 x 800|
|Day's range||107.29 - 108.98|
|52-week range||78.71 - 122.16|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||35.36|
|Forward dividend & yield||1.57 (1.46%)|
|Ex-dividend date||25 Mar 2022|
|1y target est||130.92|
Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.